ORIGINAL RESEARCH
Published on 15 Jan 2025
Suppression of MCP-1, IFN-γ and IL-6 production of HNSCC ex vivo by pembrolizumab added to docetaxel and cisplatin (TP) exceeding those of TP alone is linked to improved survival
doi 10.3389/fimmu.2024.1473897
- 412 views